"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions

In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients.Building on a complex multiple myeloma case introduced in Part 1, this segment focuses on acute decision-making in the hospital setting. The discussion highlights how to differentiate thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS), when to initiate plasma exchange, and how clinicians approach complement inhibition in time-sensitive, high-stakes scenarios.Through expert insights and practical considerations, the panel walks through key diagnostic clues including peripheral smear findings, LDH elevation, and clinical presentation, while also addressing the realities of delayed lab results, treatment access, and institutional protocols.Listen in as they unpack how to act quickly, think critically, and navigate uncertainty to optimize outcomes in patients with suspected TMA.